An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
Recruiting now · Phase 3
Conditions studied: Guillain-Barre Syndrome
In brief
The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.
Key facts
- Study ID
- NCT07020819
- Run by
- Annexon, Inc.
- People needed
- 30
- Starts
- 2025-09-12
- Expected to finish
- 2028-06-30
- Last updated by the study team
- 2026-05-28
Who can join
Age: 12 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
Where it is running
- St. Joseph's Hospital & Medical Center - Barrow Neurological Institute — Phoenix, Arizona, United States (enrolling)
- HonorHealth Bob Bové Neuroscience Institute — Scottsdale, Arizona, United States (enrolling)
- Profound Research LLC — Carlsbad, California, United States (enrolling)
- Children's Hospital of Orange County — Orange, California, United States (enrolling)
- University of California Irvine — Orange, California, United States (enrolling)
- University of Colorado Hospital — Aurora, Colorado, United States (enrolling)
- Mayo Clinic Florida — Jacksonville, Florida, United States (enrolling)
- University of Kansas Medical Center — Kansas City, Kansas, United States (enrolling)
- Ochsner LSU Health — Shreveport, Louisiana, United States (enrolling)
- University Massachusetts Chan Medical School — Worcester, Massachusetts, United States (enrolling)
- Henry Ford Health — Detroit, Michigan, United States (enrolling)
- Mayo Rochester — Rochester, Minnesota, United States (enrolling)
- Aarhus University Hospital — Aarhus, Aarhus N, Denmark (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.